CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.

MLA

Roberto, Michela, et al. “CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.” Cancers, vol. 13, no. 2, Jan. 2021. EBSCOhost, https://doi.org/10.3390/cancers13020332.

APA

Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., Minelli, M., Orlandi, A., Pantano, F., Paris, I., Pizzuti, L., Portarena, I., Salesi, N., Scagnoli, S., Scavina, P., … Marchetti, P. (2021). CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers, 13(2). https://doi.org/10.3390/cancers13020332

Chicago

Roberto, Michela, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D’Auria, Agnese Fabbri, et al. 2021. “CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.” Cancers 13 (2). doi:10.3390/cancers13020332.